Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

HemaSphere·2026
Same author

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee.

Bone marrow transplantation·2026
Same author

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Bone marrow transplantation·2026
Same author

Production and characterization of gigastasin, a leech-derived inhibitor of complement and coagulation pathways.

Scientific reports·2026
Same author

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Journal of medicinal chemistry·2026
Same author

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

NEJM evidence·2026
Same journal

A novel JAK1 mutation identified in a patient with severe atopic dermatitis phenotype: Mechanistic insights and IL-4Rα targeted therapy.

Clinical immunology (Orlando, Fla.)·2026
Same journal

VNN1 aggravates sepsis by promoting inflammation and oxidative stress through PPARγ signaling VNN1 in sepsis.

Clinical immunology (Orlando, Fla.)·2026
Same journal

Comparison between glioblastoma and brain metastases: How epigenetic remodeling can enhance immunotherapy.

Clinical immunology (Orlando, Fla.)·2026
Same journal

JAK-STAT3-MYC axis defines pathogenic stem cell-like memory CD4<sup>+</sup> T cells in rheumatoid arthritis.

Clinical immunology (Orlando, Fla.)·2026
Same journal

The baseline vaginal immune milieu is an important determinant of the inflammatory response induced by penile-vaginal sex.

Clinical immunology (Orlando, Fla.)·2026
Same journal

Adulthood diagnosis of Nijmegen breakage syndrome in twins with antibody deficiency clinical presentation.

Clinical immunology (Orlando, Fla.)·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Applying complement therapeutics to rare diseases.

Edimara S Reis1, Dimitrios C Mastellos2, Despina Yancopoulou3

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Clinical Immunology (Orlando, Fla.)
|September 6, 2015
PubMed
Summary
This summary is machine-generated.

Complement therapeutics show promise for treating rare diseases by restoring immune balance. This review highlights pipeline candidates and their mechanisms for orphan diseases.

Keywords:
Autoimmune diseasesC1 inhibitorComplementCompstatinEculizumabOrphan drugsRare diseases

More Related Videos

Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.8K
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.1K

Related Experiment Videos

Last Updated: Apr 4, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.8K
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.1K

Area of Science:

  • Immunology
  • Rare Diseases
  • Pharmacology

Background:

  • Rare diseases affect 350 million globally, often with genetic, infectious, or autoimmune origins and an inflammatory component.
  • Developing effective treatments for rare diseases is challenging due to low prevalence and limited understanding of disease mechanisms.
  • The complement system, a key inflammatory trigger, is implicated in various diseases and presents a viable therapeutic target.

Purpose of the Study:

  • To review complement therapeutics in the pharmaceutical pipeline for orphan diseases.
  • To discuss the molecular mechanisms of complement in rare disease pathogenesis.
  • To highlight the potential of complement inhibition in treating inflammatory rare diseases.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of complement system's role in rare disease pathogenesis.
  • Examination of complement therapeutics in preclinical and clinical development.

Main Results:

  • Growing evidence supports the safety and efficacy of complement therapeutics in rare diseases like hereditary angioedema and paroxysmal nocturnal hemoglobinuria.
  • Several complement-targeting drugs are in development for various orphan diseases.
  • Complement therapeutics can restore immune balance and improve clinical outcomes in rare inflammatory conditions.

Conclusions:

  • Complement therapeutics represent a promising strategy for treating a range of rare diseases.
  • Understanding complement's role in disease pathogenesis is crucial for developing targeted therapies.
  • Clinical success in existing rare disease treatments validates complement inhibition as a therapeutic approach.